Evogene Ltd. (TLV:EVGN)

Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 34.01 million. The enterprise value is 57.24 million.

Market Cap	34.01M
Enterprise Value	57.24M

Important Dates

The next estimated earnings date is Thursday, November 20, 2025.

Earnings Date	Nov 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Evogene has 8.72 million shares outstanding. The number of shares has increased by 32.03% in one year.

Current Share Class	8.72M
Shares Outstanding	8.72M
Shares Change (YoY)	+32.03%
Shares Change (QoQ)	+6.29%
Owned by Insiders (%)	0.99%
Owned by Institutions (%)	1.86%
Float	8.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.07
PB Ratio	0.82
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.19
EV / Sales	1.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.93

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.21.

Current Ratio	1.89
Quick Ratio	0.86
Debt / Equity	0.21
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	-20.80

Financial Efficiency

Return on equity (ROE) is -89.34% and return on invested capital (ROIC) is -67.78%.

Return on Equity (ROE)	-89.34%
Return on Assets (ROA)	-32.39%
Return on Invested Capital (ROIC)	-67.78%
Return on Capital Employed (ROCE)	-103.59%
Revenue Per Employee	271,963
Profits Per Employee	-410,450
Employee Count	117
Asset Turnover	0.25
Inventory Turnover	2.68

Taxes

In the past 12 months, Evogene has paid 30,324 in taxes.

Income Tax	30,324
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.06% in the last 52 weeks. The beta is 1.57, so Evogene's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	-48.06%
50-Day Moving Average	418.23
200-Day Moving Average	461.72
Relative Strength Index (RSI)	38.50
Average Volume (20 Days)	46,496

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 31.82 million and -48.02 million in losses. Loss per share was -7.21.

Revenue	31.82M
Gross Profit	19.39M
Operating Income	-65.38M
Pretax Income	-48.61M
Net Income	-48.02M
EBITDA	-60.07M
EBIT	-65.38M
Loss Per Share	-7.21

Balance Sheet

The company has 39.39 million in cash and 8.96 million in debt, giving a net cash position of 30.43 million or 3.49 per share.

Cash & Cash Equivalents	39.39M
Total Debt	8.96M
Net Cash	30.43M
Net Cash Per Share	3.49
Equity (Book Value)	41.70M
Book Value Per Share	-1.37
Working Capital	45.32M

Cash Flow

In the last 12 months, operating cash flow was -59.36 million and capital expenditures -1.96 million, giving a free cash flow of -61.32 million.

Operating Cash Flow	-59.36M
Capital Expenditures	-1.96M
Free Cash Flow	-61.32M
FCF Per Share	-7.04

Margins

Gross margin is 60.93%, with operating and profit margins of -205.46% and -150.92%.

Gross Margin	60.93%
Operating Margin	-205.46%
Pretax Margin	-152.75%
Profit Margin	-150.92%
EBITDA Margin	-188.78%
EBIT Margin	-205.46%
FCF Margin	n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.03%
Shareholder Yield	-32.03%
Earnings Yield	-141.20%
FCF Yield	-180.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 28, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Evogene has an Altman Z-Score of -12.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.37
Piotroski F-Score	2